David Dornan - Feb 15, 2024 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Robert Yang, Attorney-in-Fact
Stock symbol
ELEV
Transactions as of
Feb 15, 2024
Transactions value $
$0
Form type
4
Date filed
2/20/2024, 04:52 PM
Previous filing
Feb 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +225K $0.00 225K Feb 15, 2024 Common Stock 225K $2.77 Direct F1
transaction ELEV Restricted Stock Unit Award $0 +37.5K $0.00 37.5K Feb 15, 2024 Common Stock 37.5K Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 15, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 25% of the RSUs vest on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4 The RSUs do not expire; they either vest or are canceled prior to the vesting date.